Skip to main content
Erschienen in: Obesity Surgery 6/2017

17.12.2016 | Original Contributions

Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery

verfasst von: Elisenda Climent, David Benaiges, Juan Pedro-Botet, Juana A. Flores-Le Roux, Jose M. Ramón, Montserrat Villatoro, Laia Fontané, Juan J. Chillarón, Albert Goday

Erschienen in: Obesity Surgery | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Given the lack of evidence of the effect of bariatric surgery (BS) on atherogenic dyslipidemia (AD), which is a characteristic of obese subjects, this study aimed to describe the remission rate of AD 1 year after BS in severely obese patients.

Materials and Methods

A non-randomised, prospective cohort study was conducted in patients undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy with a 1-year follow-up. AD was defined as triglycerides ≥1.71 mmol/l or treatment with fibrates and low high-density lipoprotein (HDL) cholesterol (<1.03 mmol/l in men or <1.3 mmol/l in women).

Results

AD was present in 81 (22.8%) of the 356 patients; these were more frequently men and presented higher total cholesterol and non-HDL cholesterol concentrations. AD remission rate was 74.1% at 3 months, 90.1% at 6 months and 96.3% at 12 months, respectively, after BS. In this group of patients, HDL cholesterol levels rose progressively (1.0 ± 0.2 to 1.5 ± 0.3 mmol/l, p < 0.001) and triglycerides decreased (2.5 ± 0.9 to 1.2 ± 0.5 mmol/l, p < 0.001) during follow-up. Regarding previous lipid-lowering therapy, fibrates and ezetimibe were withdrawn in all patients and statins in 69.4% 1 year after surgery.

Conclusion

BS has beneficial effects on lipid profile, achieving complete remission of AD at 1 year of follow-up in almost all patients.
Literatur
1.
Zurück zum Zitat Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495–506.CrossRefPubMed Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495–506.CrossRefPubMed
2.
Zurück zum Zitat Grundy S, Small LDL. Atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1–4.CrossRefPubMed Grundy S, Small LDL. Atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1–4.CrossRefPubMed
3.
Zurück zum Zitat Piepoli MF, Hoes AW, Agewall S, et al., 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81. Piepoli MF, Hoes AW, Agewall S, et al., 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81.
4.
Zurück zum Zitat Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH 2013 ACC/AHA guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH 2013 ACC/AHA guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934.
5.
Zurück zum Zitat Millán Núñez-Cortés J, Pedro-Botet J, Brea-Hernando Á, et al. Use of expert consensus to improve atherogenic dyslipidemia management. Rev Esp Cardiol. 2014;67:36–44.CrossRefPubMed Millán Núñez-Cortés J, Pedro-Botet J, Brea-Hernando Á, et al. Use of expert consensus to improve atherogenic dyslipidemia management. Rev Esp Cardiol. 2014;67:36–44.CrossRefPubMed
6.
Zurück zum Zitat Pedro-Botet J, Mantilla-Morató T, Díaz-Rodríguez Á, et al. The role of atherogenic dyslipidaemia in clinical practice guidelines. Clin Investig Arterioscler. 2016;28:65–70.CrossRefPubMed Pedro-Botet J, Mantilla-Morató T, Díaz-Rodríguez Á, et al. The role of atherogenic dyslipidaemia in clinical practice guidelines. Clin Investig Arterioscler. 2016;28:65–70.CrossRefPubMed
7.
Zurück zum Zitat Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefPubMed Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefPubMed
8.
Zurück zum Zitat Sjöström L, Lindroos A-K, Peltonen M, et al. Swedish Obese Subjects study scientific group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.CrossRefPubMed Sjöström L, Lindroos A-K, Peltonen M, et al. Swedish Obese Subjects study scientific group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.CrossRefPubMed
9.
Zurück zum Zitat Benaiges D, Sagué M, Flores-Le Roux JA, et al. Predictors of hypertension remission and recurrence after bariatric surgery. Am J Hypertens. 2016;29:653–9.CrossRefPubMed Benaiges D, Sagué M, Flores-Le Roux JA, et al. Predictors of hypertension remission and recurrence after bariatric surgery. Am J Hypertens. 2016;29:653–9.CrossRefPubMed
10.
Zurück zum Zitat Vidal J, Ibarzabal A, Romero F, et al. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008;18:1077–82.CrossRefPubMed Vidal J, Ibarzabal A, Romero F, et al. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008;18:1077–82.CrossRefPubMed
11.
Zurück zum Zitat Carswell KA, Belgaumkar AP, Amiel SA, et al. Systematic review and meta-analysis of the effect of gastric bypass surgery on plasma lipid levels. Obes Surg. 2016;26:834–55.CrossRef Carswell KA, Belgaumkar AP, Amiel SA, et al. Systematic review and meta-analysis of the effect of gastric bypass surgery on plasma lipid levels. Obes Surg. 2016;26:834–55.CrossRef
12.
Zurück zum Zitat National Institutes of Health. Consensus development conference draft statement on gastrointestinal surgery for severe obesity. Obes Surg. 1991;1:257–65.CrossRef National Institutes of Health. Consensus development conference draft statement on gastrointestinal surgery for severe obesity. Obes Surg. 1991;1:257–65.CrossRef
13.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed
14.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.CrossRefPubMed Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.CrossRefPubMed
15.
Zurück zum Zitat Genuth S, Alberti KGMM, Bennett P, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7.CrossRefPubMed Genuth S, Alberti KGMM, Bennett P, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7.CrossRefPubMed
16.
Zurück zum Zitat Brethauer SA, Kim J, Chaar M El, Papasavas P, Eisenberg D, Rogers A, et al. ASMBS Clinical Issues Committee. Standardized outcomes reporting in metabolic and bariatric surgery. Obes Surg 2015;25:587–606. Brethauer SA, Kim J, Chaar M El, Papasavas P, Eisenberg D, Rogers A, et al. ASMBS Clinical Issues Committee. Standardized outcomes reporting in metabolic and bariatric surgery. Obes Surg 2015;25:587–606.
17.
Zurück zum Zitat Grundy SM, Brewer HB, Cleeman JI, et al. American Heart Association, National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.CrossRefPubMed Grundy SM, Brewer HB, Cleeman JI, et al. American Heart Association, National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.CrossRefPubMed
18.
Zurück zum Zitat González-Juanatey JR, Millán J, Alegría E, et al. Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study. Rev Esp Cardiol. 2011;64:286–94. González-Juanatey JR, Millán J, Alegría E, et al. Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study. Rev Esp Cardiol. 2011;64:286–94.
19.
Zurück zum Zitat Pedro-Botet J, Flores-Le Roux JA, Mostaza JM, et al. Atherogenic dyslipidemia: prevalence and management in lipid clinics. Rev Clin Esp. 2014;214:491–8.CrossRefPubMed Pedro-Botet J, Flores-Le Roux JA, Mostaza JM, et al. Atherogenic dyslipidemia: prevalence and management in lipid clinics. Rev Clin Esp. 2014;214:491–8.CrossRefPubMed
20.
Zurück zum Zitat Benaiges D, Flores-Le-Roux JA, Pedro-Botet J, et al. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile. Obes Surg. 2012;22:1268–75.CrossRefPubMed Benaiges D, Flores-Le-Roux JA, Pedro-Botet J, et al. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile. Obes Surg. 2012;22:1268–75.CrossRefPubMed
21.
Zurück zum Zitat Courcoulas AP, Christian NJ, Belle SH, et al. Longitudinal assessment of bariatric surgery (LABS) consortium. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013;310:2416–25.PubMedPubMedCentral Courcoulas AP, Christian NJ, Belle SH, et al. Longitudinal assessment of bariatric surgery (LABS) consortium. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013;310:2416–25.PubMedPubMedCentral
22.
Zurück zum Zitat Asztalos BF, Swarbrick MM, Schaefer EJ, et al. Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. J Lipid Res. 2010;51:2405–12.CrossRefPubMedPubMedCentral Asztalos BF, Swarbrick MM, Schaefer EJ, et al. Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. J Lipid Res. 2010;51:2405–12.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Habib P, Scrocco JD, Terek M, et al. Effects of bariatric surgery on inflammatory, functional and structural markers of coronary atherosclerosis. Am J Cardiol. 2009;104:1251–5.CrossRefPubMed Habib P, Scrocco JD, Terek M, et al. Effects of bariatric surgery on inflammatory, functional and structural markers of coronary atherosclerosis. Am J Cardiol. 2009;104:1251–5.CrossRefPubMed
24.
Zurück zum Zitat Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146:143–8.CrossRefPubMed Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146:143–8.CrossRefPubMed
25.
Zurück zum Zitat Woelnerhanssen B, Peterli R, Steinert RE, et al. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy—a prospective randomized trial. Surg Obes Relat Dis. 2007;7:561–8.CrossRef Woelnerhanssen B, Peterli R, Steinert RE, et al. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy—a prospective randomized trial. Surg Obes Relat Dis. 2007;7:561–8.CrossRef
26.
Zurück zum Zitat Mclaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern. Medicine. 2003;139:802–9. Mclaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern. Medicine. 2003;139:802–9.
27.
Zurück zum Zitat Millán J, Pintó X, Muñoz A, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757–65.PubMedPubMedCentral Millán J, Pintó X, Muñoz A, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757–65.PubMedPubMedCentral
28.
Zurück zum Zitat Garcia-Marirrodriga I, Amaya-Romero C, Ruiz-Diaz GP, et al. Evolution of lipid profiles after bariatric surgery. Obes Surg. 2012;22:609–16.CrossRefPubMed Garcia-Marirrodriga I, Amaya-Romero C, Ruiz-Diaz GP, et al. Evolution of lipid profiles after bariatric surgery. Obes Surg. 2012;22:609–16.CrossRefPubMed
29.
Zurück zum Zitat Leyba JL, Aulestia SN, Llopis SN. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for the treatment of morbid obesity. A prospective study of 117 patients. Obes Surg. 2011;21:212–6.CrossRefPubMed Leyba JL, Aulestia SN, Llopis SN. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for the treatment of morbid obesity. A prospective study of 117 patients. Obes Surg. 2011;21:212–6.CrossRefPubMed
30.
Zurück zum Zitat Pihlajamäki J, Grönlund S, Simonen M, et al. Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after gastric banding. Metabolism. 2010;59:866–72.CrossRefPubMed Pihlajamäki J, Grönlund S, Simonen M, et al. Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after gastric banding. Metabolism. 2010;59:866–72.CrossRefPubMed
31.
Zurück zum Zitat Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56–65.CrossRefPubMed Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56–65.CrossRefPubMed
32.
Zurück zum Zitat Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211–9.CrossRefPubMed Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211–9.CrossRefPubMed
Metadaten
Titel
Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery
verfasst von
Elisenda Climent
David Benaiges
Juan Pedro-Botet
Juana A. Flores-Le Roux
Jose M. Ramón
Montserrat Villatoro
Laia Fontané
Juan J. Chillarón
Albert Goday
Publikationsdatum
17.12.2016
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 6/2017
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-016-2504-6

Weitere Artikel der Ausgabe 6/2017

Obesity Surgery 6/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.